Skip to Content

Tanzeum Approval History

  • FDA approved: Yes (First approved April 15th, 2014)
  • Brand name: Tanzeum
  • Generic name: albiglutide
  • Dosage form: Injection
  • Company: GlaxoSmithKline
  • Treatment for: Diabetes, Type 2

Tanzeum (albiglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist for the treatment of type 2 diabetes.

Development History and FDA Approval Process for Tanzeum

Apr 15, 2014Approval FDA Approves Tanzeum (albiglutide) to Treat Type 2 Diabetes
Aug  2, 2013Regulatory Update: Albiglutide US PDUFA Date Extended by Three Months
Jan 14, 2013GSK Announces Submission of Albiglutide BLA to the US FDA for the Treatment of Type 2 Diabetes

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.